,

Rev Esp Quimioter 2022;35(Suppl.1):40-42

Ceftazidime-avibactam

FRANCISCO SANZ HERRERO

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.09.2022

The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa, and other enterobacteria. Compared to carbapenems, ceftazidime-avibactam has demonstrated non-inferiority in the treatment of nosocomial pneumonia including better clinical and microbiological cure rates and mortality compared to colistin. The limitation of ceftazidime-avibactam in the treatment of infections caused by metallo-beta-lactamase-producing Enterobacteriaceae can be overcome with the addition of aztreonam.

Rev Esp Quimioter 2022; 35(Suppl. 1):40-42 [Full-text PDF]


/por
Rev Esp Quimioter 2022;35(Suppl.1):35-39Rev Esp Quimioter 2022;35(Suppl.1):43-45